Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1990 2
1991 1
1992 1
1993 1
1994 2
1995 1
1996 1
1997 3
1998 2
1999 7
2000 1
2001 2
2003 3
2004 3
2005 1
2006 1
2007 1
2008 4
2009 4
2010 2
2011 2
2012 2
2013 4
2014 2
2015 2
2016 3
2017 2
2018 5
2019 3
2020 3
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Results by year
Filters applied: . Clear all
Page 1
Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.
Roopkumar J, Swaidani S, Kim AS, Thapa B, Gervaso L, Hobbs BP, Wei W, Alban TJ, Funchain P, Kundu S, Sangwan N, Rayman P, Pavicic PG Jr, Diaz-Montero CM, Barnard J, McCrae KR, Khorana AA. Roopkumar J, et al. Among authors: rayman p. Med (N Y). 2021 Apr 9;2(4):423-434. doi: 10.1016/j.medj.2021.02.002. Epub 2021 Mar 12. Med (N Y). 2021. PMID: 34036293 Free PMC article.
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P. Ornstein MC, et al. Among authors: rayman p. Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Urol Oncol. 2018. PMID: 29606341 Review.
Mechanisms of immune dysfunction in renal cell carcinoma.
Derweesh IH, Tannenbaum CS, Rayman PA, Finke JH. Derweesh IH, et al. Among authors: rayman pa. Cancer Treat Res. 2003;116:29-51. doi: 10.1007/978-1-4615-0451-1_2. Cancer Treat Res. 2003. PMID: 14650824 Review. No abstract available.
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH. Cohen PA, et al. Among authors: rayman pa. Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Immunol Invest. 2012. PMID: 23017141 Free PMC article. Review.
Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.
Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, Wallace W, Rini BI, Morris-Stiff G, Allende DS, Hamilton T, Finke JH, Diaz-Montero CM. Tannenbaum CS, et al. Among authors: rayman pa. Cancer Immunol Res. 2019 Oct;7(10):1687-1699. doi: 10.1158/2326-6066.CIR-18-0578. Epub 2019 Aug 22. Cancer Immunol Res. 2019. PMID: 31439615 Free PMC article.
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
Sheng IY, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan TD, Rini BI, Garcia JA, Grivas P, Ornstein MC. Sheng IY, et al. Among authors: rayman p. Target Oncol. 2020 Apr;15(2):211-220. doi: 10.1007/s11523-020-00707-z. Target Oncol. 2020. PMID: 32207064
69 results